Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients?

被引:8
|
作者
Danielak, Dorota [1 ]
机构
[1] Poznan Univ Med Sci, Dept Phys Pharm & Pharmacokinet, Swiecickiego 6 St, PL-60781 Poznan, Poland
关键词
Depressive disorder; major; antidepressive agents; vortioxetine; pharmacokinetics; adverse effects; cognition;
D O I
10.1080/14656566.2021.1880567
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Depressive disorders are common in older patients, and their prevalence may reach up to 17.1%. Though for older adults, the initial recommended treatment is either life-review treatment or group cognitive-behavioral therapy, a combination of pharmacotherapy with interpersonal psychotherapy is also an option. There are many classes of antidepressants, and some meta-analyses suggest that the efficacy of different antidepressant groups is similar. Therefore, depression treatment in an elderly patient should consider preference, safety, and tolerability. Most reports suggest that SSRIs, such as citalopram, escitalopram, or sertraline, should be proposed as first-time medications. Areas covered: This article discusses the pharmacokinetic and pharmacodynamic properties of vortioxetine, emphasizing the observed differences, benefits, and risks for older patients. Vortioxetine - a multimodal antidepressant drug - was shown to be effective against major depressive disorders in both double-blinded, placebo-controlled trials and open-label studies. Expert opinion: Compared with commonly used antidepressants, vortioxetine appears to have unique properties that may be beneficial for elderly patients. Not only does it enhance cognitive function, but it also has a favorable safety profile.
引用
收藏
页码:1167 / 1177
页数:11
相关论文
共 50 条
  • [1] Vortioxetine: A new alternative for the treatment of major depressive disorder
    Salagre, Estela
    Grande, Ida
    Sole, Brisa
    Sanchez-Moreno, Jose
    Vieta, Eduard
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2018, 11 (01): : 48 - 59
  • [2] Vortioxetine for the treatment of major depressive disorder
    Tritschler, Laurent
    Felice, Daniela
    Colle, Romain
    Guilloux, Jean-Philippe
    Corruble, Emmanuelle
    Gardier, Alain Michel
    David, Denis Joseph
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (06) : 731 - 745
  • [3] The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
    Cao, Bing
    Park, Caroline
    Subramaniapillai, Mehala
    Lee, Yena
    Lacobucci, Michelle
    Mansur, Rodrigo B.
    Zuckerman, Hannah
    Phan, Lee
    McIntyre, Roger S.
    FRONTIERS IN PSYCHIATRY, 2019, 10
  • [4] Vortioxetine in the treatment of major depressive disorder
    Baldwin, David S.
    Hanumanthaiah, Venkatesh Ballagere
    FUTURE NEUROLOGY, 2015, 10 (02) : 79 - 89
  • [5] The efficacy of vortioxetine for the treatment of major depressive disorder
    Dhir, Ashish
    Sarvaiya, Jayrajsinh
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (12) : 1349 - 1363
  • [6] Vortioxetine: a New Treatment for Major Depressive Disorder
    Connolly, K. Ryan
    Thase, Michael E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 421 - 431
  • [7] Levomilnacipran and vortioxetine:Review of new pharmacotherapies for major depressive disorder
    Mei T Liu
    Megan E Maroney
    Evelyn R Hermes-DeSantis
    World Journal of Pharmacology, 2015, (01) : 17 - 30
  • [8] The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
    Florea, Ioana
    Loft, Henrik
    Danchenko, Natalya
    Rive, Benoit
    Brignone, Melanie
    Merikle, Elizabeth
    Jacobsen, Paula L.
    Sheehan, David V.
    BRAIN AND BEHAVIOR, 2017, 7 (03):
  • [9] Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder
    Thase, Michael E.
    Danchenko, Natalya
    Brignone, Melanie
    Florea, Ioana
    Diamand, Francoise
    Jacobsen, Paula L.
    Vieta, Eduard
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (08) : 773 - 781
  • [10] Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial
    Borhannejad, Firouzeh
    Shariati, Behnam
    Naderi, Sina
    Shalbafan, Mohammadreza
    Mortezaei, Amirhosein
    Sahebolzamani, Erfan
    Saeb, Atefe
    Mortazavi, Seyyed Hosein
    Kamalzadeh, Leila
    Aqamolaei, Ali
    Noorbala, Ahmad Ali
    Namazi-Shabestari, Alireza
    Akhondzadeh, Shahin
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (04) : 804 - 811